Iltoo Pharma

ILTOO Pharma is a biopharmaceutical company in the clinical trial phase focusing on the advancement of biotherapies that aim to restore balance to the immune system and transform the management of autoimmune and inflammatory disorders (ADs). Leveraging extensive knowledge in translational research and clinical immunology, ILTOO Pharma is at the forefront of developing regulatory T cells (Tregs)-mediated immunotherapies. ILTOO Pharma's primary product, ILT-101, represents the most cutting-edge IL-2-based therapy globally. ILTOO envisions that IL2-mediated immunotherapy, in conjunction with corticosteroids and anti-TNFs antibodies, will emerge as the next generation of treatment.